Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · Real-Time Price · USD
1.140
+0.010 (0.88%)
At close: May 12, 2025, 4:00 PM
1.140
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Company Description
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance.
It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Mark Manfredi |
Contact Details
Address: 645 Summer Street, Suite 101 Boston, Massachusetts 02210 United States | |
| Phone | 857 273 8343 |
| Website | ikenaoncology.com |
Stock Details
| Ticker Symbol | IKNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G108 |
| ISIN Number | US45175G1085 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer and Director |
| Dr. Jotin Marango M.D., Ph.D. | Chief Operating Officer, Chief Financial Officer, Head of Corporate Development and Treasurer |
| Rebecca Cohen | Senior Vice President of Investor Relations, Corporate Strategy and Communication |
| Jeffrey Ecsedy Ph.D. | Chief Development Officer |
| Bob Lally | Senior Vice President of Finance and Operations |
| David Damphousse M.S. | Senior Vice President of Clinical Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | S-4/A | Filing |
| Apr 21, 2025 | S-4/A | Filing |
| Mar 18, 2025 | S-4 | Filing |
| Mar 6, 2025 | ARS | Filing |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |